Oramed Pharmaceuticals
ORMP
30 hedge funds and large institutions have $3.22M invested in Oramed Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 30 → 30 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.79% less ownership
Funds ownership: 4.38% → 3.59% (-0.79%)
7% less call options, than puts
Call options by funds: $984K | Put options by funds: $1.06M
41% less capital inflows, than outflows
Capital inflows: $704K | Capital outflows: $1.19M
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$426K |
| 2 |
Renaissance Technologies
New York
|
+$59.2K |
| 3 |
Jane Street
New York
|
+$56.1K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$22.9K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$696K |
| 2 |
Barclays
London,
United Kingdom
|
-$140K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$66.1K |
| 4 |
BlackRock
New York
|
-$51.7K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$51K |
ORMP Hedge Fund Activity: Q4 2019 in Review
30 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2019, worth a combined $3.22M — up 33% from $2.42M a quarter earlier.
Fund positioning in ORMP was balanced in Q4 2019: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 10 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $426K. The largest seller was Sabby Management, exiting entirely with an estimated $696K sold.
- 30 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $3.22M of Oramed Pharmaceuticals stock for Q4 2019, up 33% quarter-over-quarter.
- 5 funds opened new Oramed Pharmaceuticals positions in Q4 2019 and 5 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2019 was Marshall Wace, an estimated $426K added.
- The largest Oramed Pharmaceuticals seller in Q4 2019 was Sabby Management, an estimated $696K sold.
Based on aggregated 13F filings for Q4 2019.